drugset / Trial / NCT02130674
Optimized Therapy in Severe Traumatic Brain Injured Patients
Phase 4
Completed
12 enrolled
University of Zurich
Fresenius Kabi · collabSwiss National Science Foundation · collabUniversity Hospital, Zürich · collab
NaSingle-groupOpen-labelTreatment
Summary
Severe traumatic brain injury is associated with life-threatening and incapacitating secondary injury. Contemporary therapeutic interventions are aimed at preventing and treating secondary damage. In this context, improved cerebral metabolism is an important target in modern neurointensive care. The main hypothesis is that continuous intravenous infusion of glutamyl-alanyl dipeptide restores disturbed brain metabolism following severe traumatic brain injury.
Timeline
- Start
- 2005-01
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dipeptiven | Peptide | 0.75 g/kg | Intravenous |